Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease

Maria C. Carrillo, H. Robert Brashear, Veronika Logovinsky, J. Michael Ryan, Howard H. Feldman, Eric R. Siemers, Susan Abushakra, Dean M. Hartley, Ronald C. Petersen, Ara S. Khachaturian, Reisa A. Sperling

Research output: Contribution to journalArticlepeer-review

85 Scopus citations


Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.

Original languageEnglish (US)
Pages (from-to)123-131.e1
JournalAlzheimer's and Dementia
Issue number2
StatePublished - Mar 2013


  • Alzheimer's disease
  • Diagnosis
  • Mild cognitive impairment
  • Preclinical Alzheimer's
  • Prevention

ASJC Scopus subject areas

  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Health Policy
  • Developmental Neuroscience
  • Epidemiology


Dive into the research topics of 'Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this